我們已在上線! 進一步了解
MMSI圖示

Merit Medical Systems

89.20 USD
-0.37
0.41%
收盤時 已更新 10月16日 下午4:00 EDT
盤前交易
盤後交易
89.20
0.00
0%
1天
-0.41%
5天
1.77%
1個月
3.55%
3個月
18.07%
6個月
27.25%
今年迄今
3.18%
1年
10.38%
5年
28.88%
10年
277.97%
 

關於: Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.

員工: 7,500

新聞

正面
中性
負面
市場情緒 3個月
正面 51.9%
中性 44.4%
負面 3.7%
正面
Zacks Investment Research
7 天前
Cancer Stocks to Consider as Oncology Innovation Accelerates
Oncology stocks are gaining relevance as cancer care evolves, with Pfizer, Merit Medical Systems and Abbott advancing treatments, diagnostics and screening technologies.
Cancer Stocks to Consider as Oncology Innovation Accelerates
中性
GlobeNewsWire
10 天前
Merit Medical Systems to Announce Third Quarter 2026 Results on October 29, 2026
SOUTH JORDAN, Utah, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that it will release its financial results for the quarter ended September 30, 2026, after the close of the stock market on Thursday, October 29, 2026. Merit plans to hold its investor conference call on the same day (Thursday, October 29, 2026) at 4:30 p.m. Eastern (3:30 p.m. Central, 2:30 p.m. Mountain, and 1:30 p.m. Pacific).
Merit Medical Systems to Announce Third Quarter 2026 Results on October 29, 2026
中性
Zacks Investment Research
10 天前
HSIC or MMSI: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Henry Schein (HSIC) or Merit Medical (MMSI). But which of these two stocks presents investors with the better value opportunity right now?
HSIC or MMSI: Which Is the Better Value Stock Right Now?
中性
Zacks Investment Research
10 天前
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now
MMSI's broad product portfolio, global expansion and strategic M&A support growth, while tariffs and China pressures remain key risks.
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now
正面
Zacks Investment Research
15 天前
5 Medical Dental Supply Stocks to Watch as Industry Prospects Improve
Here, we highlight five medical supplies stocks, MCK, CAH, BDX, MMSI and PDEX, with strong potential that investors should keep on their watchlist amid improving industry prospects.
5 Medical Dental Supply Stocks to Watch as Industry Prospects Improve
中性
GlobeNewsWire
上個月
Merit Medical to Participate in Upcoming Investors Conferences in September
SOUTH JORDAN, Utah, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced that management is scheduled to participate in the following upcoming investor conferences:
Merit Medical to Participate in Upcoming Investors Conferences in September
中性
Zacks Investment Research
上個月
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now
MMSI's broad portfolio, R&D investments and WRAPSODY opportunity support growth, while tariffs, China pressure and competition remain risks.
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now
中性
Zacks Investment Research
上個月
Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing cancer-focused therapies and technologies.
Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
正面
Zacks Investment Research
上個月
Should You Buy MMSI as Growth Improves but Valuation Stays Elevated?
Merit Medical's growth case is strengthening as launches, acquisitions and therapeutic products broaden its mix, but its premium valuation raises the execution bar.
Should You Buy MMSI as Growth Improves but Valuation Stays Elevated?
正面
Zacks Investment Research
上個月
Can MMSI Sustain Its 22.2% Gain in the Past Month as Growth Improves?
Merit Medical's 22.2% monthly rally gains support from stronger Q2 growth and a raised 2026 outlook, but valuation and tariff risks remain.
Can MMSI Sustain Its 22.2% Gain in the Past Month as Growth Improves?
價格圖表採用Lightweight Charts™實作